Hengrui Medicine (1276.HK) surged 9.57% in Hong Kong trading to HK$49.000, spiking more than 5% within five minutes at one point during the session.
Third-quarter net profit soared 89% year on year to RMB 2.458 billion, far exceeding market expectations. Revenue climbed 20.55% to RMB 8.95 billion, driven by robust innovative drug sales and a 31% increase in licensing income that included a major deal with Novo Nordisk.
For the first nine months, net profit attributable to shareholders rose 20.38% from a year earlier.
